Abbey Barkley Davis, NP
Family · Providence, RINPI 1568179547
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 339 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $4,409 and has fallen 99.4% since, to $28 in 2025. Among family clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 339 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$914
- Novo Nordisk$813
- Pfizer$657
- AstraZeneca$589
- GSK$508
- Bayer$354
- plus $3K from 25 others
What the payments were for
- Food & beverage$6,97299%
- Education$1051%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $914 |
| Novo Nordisk | 41 | $813 |
| Pfizer | 34 | $657 |
| AstraZeneca | 28 | $589 |
| GSK | 24 | $508 |
| Bayer | 14 | $354 |
| Lundbeck LLC | 14 | $322 |
| Exact Sciences | 17 | $318 |
| E.r. Squibb & Sons, L.L.C. | 13 | $260 |
| Idorsia Pharmaceuticals US Inc | 13 | $254 |
| Otsuka America Pharmaceutical, Inc. | 8 | $248 |
| Lilly USA, LLC | 13 | $221 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $190 |
| Mylan Specialty L.p. | 8 | $177 |
| Boehringer Ingelheim | 7 | $172 |
| CMP Pharma, Inc. | 8 | $160 |
| Abbott | 1 | $149 |
| Bausch Health US, LLC | 6 | $117 |
| Astellas Pharma US Inc | 2 | $104 |
| Merck | 6 | $104 |
| Sumitomo Pharma America, Inc. | 4 | $102 |
| Johnson & Johnson | 3 | $74 |
| Phathom Pharmaceuticals, Inc. | 3 | $69 |
| Actelion Pharmaceuticals US, Inc. | 2 | $57 |
| Amgen | 2 | $33 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Novartis | 1 | $20 |
| Insightec,inc | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$149
- Kerendia$112
- QULIPTA$104
- UBRELVY$104
- REXULTI$103
How this compares
$7,076 in reported general payments places this provider in the 95th percentile of 457 family providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 17 | $32,445 |
| JardianceEmpagliflozin | 19 | $18,373 |
| EliquisApixaban | 27 | $16,347 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $15,299 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $4,889 |
| Xtampza ErOxycodone Myristate | 12 | $3,410 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $3,284 |
| Atorvastatin Calcium | 90 | $1,193 |
| Omeprazole | 76 | $1,136 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $1,076 |
| Levothyroxine Sodium | 62 | $833 |
| Duloxetine Hcl | 18 | $830 |
| Hydroxyzine Hcl | 17 | $805 |
| Fluticasone Propionate | 31 | $676 |
| Amlodipine Besylate | 72 | $667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $914 | $32,44517 claims |
| Boehringer IngelheimJardiance | $172 | $18,37319 claims |
| PfizerEliquis | $657 | $16,34727 claims |
| GSKTrelegy Ellipta | $508 | $15,29923 claims |
| AstraZenecaBevespi Aerosphere | $589 | $4,88911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 457 family providers in Rhode Island.
Other family in Providence
- Jeannie-Mae DurfeeProvidence$8K
- Shandrea RodriguezProvidence$8K
- Colleen FullertonProvidence$8K
- Inna YakirevichProvidence$7K
- Dennis RotondiProvidence$5K
- Michael MoylanProvidence$5K
- Breanne St MartinProvidence$4K
- Caroline KinneyProvidence$4K
- Vanessa LopezProvidence$4K
- Bridget FitzgibbonProvidence$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.